Hormone Replacement Therapy and False Positive Recall in Breast Cancer Screening
Author Information
Author(s): Emily Banks, Gillian Reeves, Valerie Beral, Diana Bull, Barbara Crossley, Moya Simmonds, Elizabeth Hilton, Stephen Bailey, Julietta Patnick
Primary Institution: National Centre for Epidemiology and Population Health, Australian National University
Hypothesis
What is the relationship between patterns of hormone replacement therapy (HRT) use and false positive recall in breast cancer screening?
Conclusion
Current use of oestrogen-only and oestrogen-progestagen HRT increases the risk of false positive recall at screening.
Supporting Evidence
- 3,043 women were recalled to assessment, with 2,629 having false positive recall.
- Current users of HRT had a significantly higher risk of false positive recall compared to never users.
- The relative risk of false positive recall was elevated in users of oestrogen-only and oestrogen-progestagen HRT.
Takeaway
Women who use certain hormone treatments are more likely to get called back for extra tests after a mammogram, even if they don't have breast cancer.
Methodology
The study followed 87,967 postmenopausal women aged 50 to 64 years attending routine breast cancer screening and analyzed their HRT use and screening outcomes.
Potential Biases
There may be biases related to self-reported HRT use and variations in screening practices across different centers.
Limitations
The study had limited power to test for differences in the effect of HRT according to the number of mammographic views in use by different screening centres.
Participant Demographics
Postmenopausal women aged 50 to 64 years, primarily from the UK.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI 1.43–1.83 for oestrogen-only HRT
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website